Annual report and full year financial results
Filed with ASX · · 94 pages · English
No dividends have been paid or declared by the entity since the beginning of the current reporting period. No dividends were paid for the previous corresponding period. No record date for determining entitlements to dividends has been declared. Explanation of Revenue (Appendix 4E item 2.6) Explanation of Revenue (Appendix 4E item 2.6) Revenue from continuing operations of $4,884,000 (2017: $3,643,
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- VivaGel BV NDA advances to next stage of FDA review
- Starpharma licenses VivaGel BV to Mundipharma for Europe
- Mundipharma licenses Starpharmas VivaGel BV
- Appendix 4C - Quarterly Cashflow Report
- Starpharma completes US New Drug Application for VivaGel BV
Later from Starpharma
- AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
- DEP irinotecan outperforms in pancreatic cancer model
- Starpharma Investor Presentation for Citi Conference
- DEP products outperform in human pancreatic cancer model
- US VivaGel BV licensed for A$142M milestones plus royalties
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma